eCite Digital Repository
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-Β
Citation
Simpson-Yap, S and Pirmani, A and De Brouwer, E and Peeters, LM and Geys, L and Parciak, T and Helme, A and Hillert, J and Moreau, Y and Edan, G and Spelman, T and Sharmin, S and McBurney, R and Schmidt, H and Bergmann, A and Braune, S and Stahmann, A and Middleton, R and Salter, A and Bebo, B and van der Walt, A and Butzkueven, H and Ozakbas, S and Karabudak, R and Boz, C and Alroughani, R and Rojas, JI and van der Mei, I and Sciascia do Olival, G and Magyari, M and Alonso, R and Nicholas, R and Chertcoff, A and Zabalza, A and Arrambide, G and Nag, N and Descamps, A and Costers, L and Dobson, R and Miller, A and Rodrigues, P and Prckovska, V and Comi, G and Kalincik, T, Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-Β, Multiple Sclerosis and Related Disorders, 66 Article 104072. ISSN 2211-0348 (2022) [Refereed Article]
Copyright Statement
© 2022 Elsevier B.V.
DOI: doi:10.1016/j.msard.2022.104072
Abstract
Background: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS.
Results: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs.
Conclusions: In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.
Item Details
| Item Type: | Refereed Article |
|---|---|
| Keywords: | COVID-19, multiple sclerosis, Interferon-β, disease modifying therapy |
| Research Division: | Health Sciences |
| Research Group: | Epidemiology |
| Research Field: | Epidemiology not elsewhere classified |
| Objective Division: | Health |
| Objective Group: | Clinical health |
| Objective Field: | Prevention of human diseases and conditions |
| UTAS Author: | Simpson-Yap, S (Dr Steve Simpson JR) |
| UTAS Author: | van der Mei, I (Professor Ingrid van der Mei) |
| ID Code: | 154321 |
| Year Published: | 2022 |
| Deposited By: | Menzies Institute for Medical Research |
| Deposited On: | 2022-11-23 |
| Last Modified: | 2022-12-07 |
| Downloads: | 0 |
Repository Staff Only: item control page